Health News Releases - Korea Newswire

Health News Releases

Today May 2

Masimo RD SET® Neo Pulse Oximetry Sensor

April 30, 16:10

Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study

Masimo (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54524005&newsitemid=20260428136753&lan=en-US&anchor=Masimo&index=1&md5=9061676d45e4b2fdccbe6887499605e3)

Dr. Vivek Mundada with Medcare multidisciplinary medical team (Photo: AETOSWire)

April 30, 09:40

Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US

Medcare Royal Speciality Hospital (MRSH) in Dubai has become the world’s first hospital outside the USA, to offer a newly licensed intrathecal gene therapy - Itvisma, to adult patients with Spinal Mus

Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equi

April 30, 08:55

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), today announced that the compan

Credits to Roquette

April 29, 17:15

Roquette Showcases Its Expanded Consumer Healthcare Capabilities at Vitafoods Europe 2026

Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will present its expanded portfolio at Vitafoods Europe 2026 which is taking place from May 5 to May 7 in

April 29, 13:13

Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific

Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as “ATLATL”), global innovation platform for life science research and development, today announced that the companies h

PCI Pharma Services announced a series of major infrastructure investments that substantially deepen

April 28, 16:00

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities

PCI Pharma Services (“PCI”) - a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies - announced a ser

April 28, 15:40

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients

Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adu

Sun Pharma signs Definitive Agreement to Acquire Organon

April 28, 15:30

Sun Pharma signs Definitive Agreement to Acquire Organon

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (N

Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt

April 27, 15:20

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health

Today, the Higher Regional Court of Frankfurt upheld the February 2025[1] partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia

First-in-human contrast enhanced MRI images with GE HealthCare’s mangaciclanol

April 24, 13:51

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI)

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

April 24, 11:10

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Agenus (https://www.agenusbio.com/) Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma (https://bappharma.com/), a global medicines access and clinical trial supply company, t

April 23, 16:33

Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. · Strong start to the year delivering net sales of 1,47

April 23, 15:51

Galderma Shareholders Approve All Annual General Meeting Proposals

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), h

April 23, 15:00

Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Turbine, a leading virtual biology company, to advance tra

April 22, 11:10

Rigaku Enters Strategic Alliance with Onto Innovation through 27 % Equity Investment

Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), a global leader in X-ray analytical technologies, today announced that it has entered into a str

PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bi

April 21, 15:30

Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys

SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with San

April 21, 10:15

SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced t

Electron microscope image of BK virus, showing the VP1 capsid protein that creates an icosahedral sh

April 20, 09:35

Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program

Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first

April 19, 14:55

Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026

Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-dr

Figure 1: Pincushion plant (Diapensia lapponica) in bloom, growing in alpine rocky areas. Its distri

April 17, 15:30

New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample

Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President

April 16, 15:30

Invivoscribe Announces the PrepQuant™ System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows

Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the PrepQuant™ System, a novel sample preparation platform that int

April 16, 14:19

Ferring Pharmaceuticals and Gallup Announce Landmark Global Public Attitudes Study on Fertility and Family-Building

Ferring Pharmaceuticals and Gallup today announced the Ferring Global Fertility Monitor, a global study on the factors influencing people’s fertility choices, at the 2026 Annual Convening of Semafor W

April 16, 14:12

Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a leader in peptide-based reg

April 15, 08:40

Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate

Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nec

IFF showcases wellness innovation for beauty.

April 14, 10:00

IFF Explores the Science Behind Well-Being at In‑Cosmetics Global 2026

IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients and health & biosciences—will showcase scent and bioscience innovations focused on wellness and sustainability at In‑Cosmetics

Clean Cells and Naobios Showcase Complete End-to-End Viral Vaccines and Vector Solutions at Bio Kore

April 13, 11:00

Clean Cells and Naobios Showcase Complete End-to-End Viral Vaccines and Vector Solutions at Bio Korea 2026

Clean Cells (https://clean-cells.com/), a leading biopharmaceutical quality control services provider specializing in biologics GMP testing, and Naobios (https://www.naobios.com/), a CDMO (Contract De

April 10, 15:35

Byondis Appoints Christoph Korpus, PhD, MBA as Chief Executive Officer

Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces today the appointment of Christoph Korpus, PhD, MBA, as Chief Executiv

April 09, 14:40

Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause

Galderma (SIX: GALD), the pure-play dermatology category leader, today welcomes new data from two IITs, demonstrating the power of Sculptra - the first proven regenerative biostimulator - and the comp

April 08, 15:30

Variational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug Discovery

Variational AI today announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers significan

April 03, 13:30

VDYNE Receives FDA Approval to Initiate the TRIVITA[1] IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System

VDYNE, Inc. (“VDYNE” or “the Company”), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Admin

April 03, 11:30

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

Agenus (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.agenusbio.com&esheet=54475511&newsitemid=20260401039214&lan=en-US&anchor=Agenus&index=1&md5=543f2b7e0242fee88c23d833e5fff50

April 02, 14:30

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova

WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform

April 02, 10:10

WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform

WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2Fus%2Fen%2F&esheet=54472286&newsitemid=20260331399622&lan=en-US&anchor=WHOOP%2C&index=1&md5=5b3c0a4ec1e7066bef07

HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics

March 31, 09:50

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)

HistoSonics (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhistosonics.com%2F&esheet=54465795&newsitemid=20260330349844&lan=en-US&anchor=HistoSonics&index=1&md5=83f0539aafc562f523a

March 31, 09:30

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova

March 30, 09:30

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global an

March 29, 11:45

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

Takeda (TSE:4502/NYSE:TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adult

March 29, 11:25

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clin

March 29, 10:25

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova

March 27, 12:00

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging

Rubedo Life Sciences, Inc. (https://www.rubedolife.com/) (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targetin

March 27, 11:10

Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification

Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to announce that its IdentiClone Dx IGH Assay has received In Vitro Diagnostic Regulation

March 26, 16:30

Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery

MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Company”) (NYSE American: APUS), today announced that on March 20, 202

The past 12 months have marked one of the most prolific periods of product innovation in Hyperice‘s

March 25, 15:50

Hyperice Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

Hyperice (https://hyperice.com/), a high-performance wellness brand, has been named to Fast Company’s (https://www.fastcompany.com/) prestigious list of the World’s Most Innovative Companies of 2026.

March 24, 16:39

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs

Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual

Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Libr

March 24, 15:20

Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova

March 23, 15:50

Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.

March 20, 15:52

Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting

Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22,

Samsung Bioepis office in Songdo, Incheon, Republic of Korea

March 18, 16:38

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under d

March 18, 15:55

DNA Script Expands Global Access to On-demand DNA Synthesis With Distributor Agreements in Latin America and East Asia

DNA Script, a pioneer in DNA synthesis providing scientists with rapid, on-demand access to high-quality DNA, today announced it has signed distribution agreements with Gencell (https://cts.businesswi

March 17, 16:20

Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay

H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse

March 17, 16:00

AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies

Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics por

March 17, 11:30

SBC Medical Announces Opening of Brand Flagship “NEO Skin Clinic Ginza.”

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields,

March 16, 09:23

Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide

Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research collaboration and license agreement with

WHOOP and Samuel Ross MBE Announce First Limited-Edition Collection Drop for PROJECT TERRAIN

March 15, 13:30

WHOOP and Samuel Ross MBE Announce First Limited-Edition Collection Drop for PROJECT TERRAIN

WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%3Futm_source%3DPR%26utm_medium%3DPR%26utm_campaign%3DSR_A&esheet=54443959&newsitemid=20260312513358&lan=en-US&anc

March 13, 15:55

C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests to Help Doctors Diagnose Alzheimer’s Disease

C2N Diagnostics, LLC (https://c2n.com/) (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, has reached an agreement with BeauBrain Healthcare (https://beaubra

March 13, 11:40

Andersen Consulting Strengthens Platform with Collaborating Firm Ambit Iberia

Andersen Consulting expands its technology and business transformation capabilities through a Collaboration Agreement with Ambit Iberia, a consulting firm specializing in digital and regulatory soluti

March 12, 16:10

Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets

Veristat (https://www.veristat.com/), a global clinical research organization (CRO) and consultancy specializing in complex studies, announced expanded regulatory and clinical trial services to intern

March 12, 15:55

InterSystems Appoints Former NHS and Mass General Leader Dr. Tim Ferris as Vice President, Healthcare Practice

InterSystems, a creative data technology provider powering more than one billion health records globally, today announced the appointment of Tim Ferris, M.D., as Vice President, Healthcare Practice. T

The Hypervolt 3 line enables users to massage away stress and tension, loosen muscle knots, maintain

March 12, 15:10

Hyperice Introduces Hypervolt 3 Line: More Powerful, Quieter, and Longer-Lasting Percussion Massage Devices

Hyperice (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhyperice.com%2F&esheet=54442271&newsitemid=20260310934508&lan=en-US&anchor=Hyperice&index=1&md5=9dae1327c39b94f4b0ce095f7d63

March 12, 08:36

Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site

Chiesi Group (“Chiesi”), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, t

March 11, 15:53

Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF

March 11, 15:52

Galderma Completes Successful Placement of EUR 500 Million Eurobond

Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Grou

WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker

March 11, 15:45

WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel

WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2Fus%2Fen%2F&esheet=54439889&newsitemid=20260310966566&lan=en-US&anchor=WHOOP&index=1&md5=45c5be6cf83ed6f2f43c9ea

March 11, 08:44

For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025

Ferring today published its 2025 Annual Report (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ferring.com%2Fwp-content%2Fuploads%2Fsites%2F16%2F2026%2F03%2FFerring-Pharmaceutic

March 10, 09:43

Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin

Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily

Medical Korea 2026 will take place at Coex, Seoul, from March 19 (Thu) to 22 (Sun), themed on ‘AI-Po

March 06, 16:22

Medical Korea 2026 Spotlights AI-Powered Global Healthcare Transformation and Cross-Border Medical Services

Medical Korea 2026 (https://www.mkconf.org/fairDash.do?hl=ENG), the 16th Global Healthcare & Medical Tourism Conference, will take place March 19-22, 2026, at COEX in Seoul. Hosted by the Ministry

March 05, 16:04

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency, and Core EBITDA of 1.211 billion USD, Growing 18.9% at Constant Currency

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. · Record net sales of 5,207 million USD, surpassing 5 billion

WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform

March 05, 15:40

WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform Globally

WHOOP (https://www.whoop.com/kr/en/), the human performance company, today announced plans to add more than 600 new roles across Software, Research & Design, Hardware, Product, and Marketing as the co

March 05, 09:20

Linnea Achieves CEP Certification for Cannabidiol Isolate

Linnea is proud to announce that its Cannabidiol (CBD) Isolate has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP). The CEP serves to attest that the quality of an act

Swiss Advanced Vision premium IOL lenses for cataract surgery

March 04, 15:50

Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance

Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cata

March 04, 11:11

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54436160&newsitemid=20260301580219&lan=en-US&anchor=TSE%3A4502%2FNYSE%

Controller and processor, Filter-less culture bag and reservoir/waste bags *Controller and other acc

March 03, 15:45

PHCbi Launches LiCellGrow™ Cell Expansion System to Support High-Quality and Efficient Production of Cell and Gene Therapies

PHC Corporation’s Biomedical Division (Head Office: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereinafter “PHCbi”), a global provider of laboratory sample storage and cell cultivation solutions

March 03, 14:20

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova

Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data

March 02, 13:30

Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data

Cowellnex Co., Ltd. (Cowellnex)—jointly established by Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and Kyowa Kirin Co., Ltd. (Kyowa Kirin)—and Metagen, Inc. (Metagen), which promotes

March 02, 11:55

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54433496&newsitemid=20260226660598&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md